You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,589,960


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,589,960
Title: Hydromorphone and hydrocodone compositions and methods for their synthesis
Abstract:A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
Inventor(s): Harclerode; William H. (Asbury, NJ), Gault; Robert (Gross Pointe Woods, MI), Sandison; Mark D. (Dearborn, MI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/256,996
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,589,960
Patent Claims: 1. A composition comprising hydromorphone and: a) from about 0.05% up to about 1.0% dihydromorphine; b) up to about 0.1% morphine; c) up to about 0.8% 8-hydroxy hydromorphone; d) up to about 0.5% bis-hydromorphone; and e) up to about 0.2% other impurities.

2. The composition of claim 1, comprising from about 0.05% up to about 0.5% dihydromorphine.

3. The composition of claim 1, comprising from about 0.0% up to about 0.05% morphine.

4. The composition of claim 1, comprising from about 0.0% up to about 0.5% 8-hydroxy hydromorphone.

5. The composition of claim 1, comprising from about 0.0% up to about 0.05% bis-hydromorphone.

6. The composition of claim 1, comprising from about 0.0% up to about 0.1 % other impurities.

7. A composition comprising hydromorphone and: a) from about 0.22% up to about 0.29% dihydromorphine; b) up to about 0.02% morphine; c) from about 0.04% up to about 0.05% 8-hydroxy hydromorphone; d) up to about 0.02% bis-hydromorphone; and e) up to about 0.06% other impurities.

8. A composition comprising hydromorphone and about 0.26% dihydromorphine; about 0.01% morphine; about 0.04% 8-hydroxy hydromorphone; about 0.02% bis-hydromorphone; and about 0.06% other impurities.

9. The composition of any one of claims 1, 7, or 8, wherein said composition is prepared by a process comprising mixing morphine with an acid in the presence of a catalyst wherein said process is carried out in the substantial absence of hydrogen gas.

10. The composition of claim 9, wherein said process further comprises heating said mixture for a period of time sufficient to yield a hydromorphone composition comprising less than about 1.0% 8-hydroxy hydromorphone.

11. The composition of claim 10, wherein said period of time is sufficient to yield a hydromorphone composition comprising less than or equal to 2.0% dihydromorphone.

12. The composition of claim 10, wherein said time is greater than about thirty minutes.

13. The composition of claim 10, wherein said time is greater than or equal to about five hours.

14. The composition of claim 9, wherein said acid is hydrochloric acid and said catalyst is non-supported palladium.

15. A composition comprising hydromorphone, from about 0.05% up to about 1.0% of dihydromorphine, and one or more compounds selected from the group consisting of morphine, 8-hydroxy hydromorphone, bis-hydromorphone, and other impurities.

16. A hydromorphone composition which is substantially free of impurities.

17. The composition of claim 16, which comprises: a) from about 0.05% up to about 1.0% dihydromorphine; b) up to about 0.1% morphine; c) up to about 0.8% 8-hydroxy hydromorphone; d) up to about 0.5% bis-hydromorphone; and e) up to about 0.2% other impurities.

18. A method of forming a pharmaceutical composition comprising a hydromorphone salt, 8-hydroxy hydromorphone and dihydromorphone by heating an aqueous mixture of said salt, 8-hydroxy hydromorphone and dihydromorphone for a time sufficient to reduce the concentration of 8-hydroxy hydromorphone to less than about 1.0%.

19. The method of claim 18, wherein said time is sufficient to reduce the concentration of dihydromorphine to less than or equal to about 2.0%.

20. The method of claim 18, wherein said aqueous mixture is obtained by mixing morphine or a salt thereof with an acid in the presence of a catalyst in the substantial absence of hydrogen gas.

21. The method of claim 20, wherein said catalyst comprises non-supported palladium.

22. The method of claim 20, wherein said acid is hydrochloric acid.

23. The method of claims 18, wherein the time is greater than about thirty minutes.

24. The method of claim 23, wherein the time is greater than or equal to about five hours.

25. The method of claim 18, wherein said salt is bisulfite.

26. The method of claim 18, wherein said pharmaceutical composition comprises hydromorphone and: a) from about 0.05% up to about 1.0% dihydromorphine; b) up to about 0.1% morphine; c) up to about 0.8% 8-hydroxy hydromorphone; d) up to about 0.5% bis-hydromorphone; and e) up to about 0.2% other impurities.

27. The composition of claim 16, wherein said composition is prepared by a process comprising heating an aqueous mixture of hydromorphone salt, 8-hydroxy hydromorphone and dihydromorphone for a time sufficient to reduce the concentration of 8-hydroxy hydromorphone to less than about 1.0%.

28. The composition of claim 27, comprising hydromorphone and: a) from about 0.05% up to about 1.0% dihydromorphine; b) up to about 0.1% morphine; c) up to about 0.8% 8-hydroxy hydromorphone; d) up to about 0.5% bis-hydromorphone; and e) up to about 0.2% other impurities.

29. The composition of claim 27, wherein said acid is hydrochloric acid and said catalyst is non-supported palladium.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.